Bayer's Oncology Rollout Meets Its Missouri Reckoning

Barclays lifted its Bayer price target to EUR 70 after FDA clearance of Hyrnuo, but the glyphosate settlement ruling remains the key catalyst.

Two regulatory wins in quick succession have shifted the conversation around Bayer back toward its medicine cabinet. On September 10, the US Food and Drug Administration cleared Sevabertinib—marketed as Hyrnuo—for use as a first-line option in advanced or metastatic lung cancer carrying a specific HER2 mutation. The green light followed a Japanese approval in August covering all lines of therapy. Barely two weeks before the US decision, the Leverkusen group had also filed in Japan for Kerendia (finerenone) in non-diabetic chronic kidney disease, leaning on positive Phase 3 data.

That flurry of pipeline news lands against a backdrop that had, for months, been defined by courtroom baggage rather than science. Barclays responded last Friday by lifting its price target on the stock from EUR 60 to EUR 70 while keeping a buy rating. The market has taken note: the shares trade at EUR 49.26, up 33 percent year to date.

The Question That Matters

Strip away the noise and the investment case comes down to a single variable—whether Bayer can grow pharmaceutical revenue fast enough to absorb its looming financial obligations without crimping the rest of the business. The planned glyphosate settlement calls for payouts of up to USD 7.25 billion, spread across as many as 21 years in declining, capped annual installments. New products such as Hyrnuo and Kerendia must fill the gap, while debt reduction keeps demanding steady free cash.

Second-quarter figures show the group generated EUR 10.87 billion in revenue and EUR 2.14 billion in adjusted EBITDA. Crop Science did the heavy lifting, posting a 30.2 percent jump in adjusted operating profit. The pharma division now has to prove it can deliver dependable growth of its own.

Where the Upside Lives

In the bull case, the recent approvals translate quickly into meaningful sales. Establishing Sevabertinib in the US and Japan would underpin margins over the long haul, with a further boost possible if Kerendia's Japanese filing wins clearance. The first-line designation widens the addressable market considerably compared with follow-on approvals, and a mid-term label expansion for Kerendia in non-diabetic kidney disease would broaden the revenue base further.

The fundamental scaffolding looks sturdier too. Management reaffirmed full-year 2026 guidance for adjusted EBITDA of EUR 9.6 billion to EUR 10.1 billion, and an agreement with funds managed by Apollo trimmed the expected net financial debt for 2026 to EUR 29–30 billion. If that deleveraging gathers pace, Bayer regains room to spend on research and strategic bets—a combination Barclays reckons could carry the stock toward its EUR 70 target.

What Could Go Wrong

Legal uncertainty remains the dominant threat. Despite the product momentum, the litigation flank is wide open. A hearing on final approval of the multibillion-dollar settlement was held last Monday, but no binding ruling has followed. Should the Missouri court reject the deal or demand changes, the specter of open US claims returns at full force, leaving the financial burden unquantifiable and the legal calm the market craves out of reach. The Eighth Circuit Court of Appeals did reject plaintiffs' bid to move the matter to federal court in late August—yet that offers no guarantee of an overarching legal resolution.

Operational hurdles compound the picture. A regulatory nod is not a commercial breakthrough. Hyrnuo must compete in the US market, and reimbursement terms still need to be negotiated. If the sales ramp proves sluggish, or if Kerendia's Japanese approval slips, fixed obligations to retire legacy liabilities would collide with weaker-than-hoped cash generation. Agricultural operations, meanwhile, carry weather and pricing risks that could quickly overshadow a strong second quarter.

The Milestones Ahead

For investors, the path forward hinges on a clear sequence of events. As long as operating results support the annual targets and the debt corridor holds, the fundamental base stays intact. But if sentiment around the US settlement sours or approval drags on, legal risks could erode the stock's recent gains in short order.

The next hard catalyst is the Missouri court's decision on final approval of the settlement—only then will it be clear whether Bayer can truly cap its legal legacy and train full attention on the pharmaceutical pipeline. Before that, the operational scorecard arrives on November 3, 2026, when the company publishes its third-quarter statement. That report will show how pharma sales are tracking in the current business and how management frames the remaining financial burden for the rest of the year.